Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CD44
REST API REST API
Homo sapiens
CD44 is differentially expressed in 444 experiments: 213 organism parts: liver, lung, ... (211 more);, 307 disease states: normal, control, ... (305 more);, 168 cell types 645 cell lines 67 compound treatments and 94 other conditions.
Synonyms MIC4, CSPG8, IN, MC56, CD44R, Pgp1, MDU2, MDU3, HCELL
Orthologs CD44 (2 of 2) (Danio rerio)   CD44 (Gallus gallus)   Q0VD03_BOVIN (Bos taurus)   CD44 (1 of 2) (Danio rerio)   Cd44 (Mus musculus)   Cd44 (Rattus norvegicus)   cd44 (Xenopus laevis)   Q28285_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytokine-mediated signaling pathway, cytoplasm, cell-cell adhesion, positive regulation of gene expression, membrane, negative regulation of apoptosis, Golgi apparatus, external side of plasma membrane, basolateral plasma membrane, cell adhesion, Wnt receptor signaling pathway, cell-matrix adhesion, integral to plasma membrane, cytokine binding, receptor activity, binding, hyaluronic acid binding, cell surface, positive regulation of peptidyl-serine phosphorylation, positive regulation of peptidyl-tyrosine phosphorylation, branching involved in ureteric bud morphogenesis, positive regulation of ERK1 and ERK2 cascade, branching involved in prostate gland morphogenesis, negative regulation of mature B cell apoptosis, wound healing involved in inflammatory response, collagen binding, negative regulation of DNA damage response, signal transduction by p53 class mediator, interferon-gamma-mediated signaling pathway, transmembrane signaling receptor activity
InterPro Term CD44_antigen, Link
UniProt Accession Q9H5A7, Q9H5A6, Q9H5A4, Q9H5A3, P16070, Q86UZ1, C0STK4, B4XHE2, C1PHC2, C1PHC3, C1PHC4, B6EAT9, O95370, C1PHE6, E7EPC6, E9PKC6
Gene-Disease Assocation INDIAN BLOOD GROUP SYSTEM; IN
Search EB-eye ENSG00000026508
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (37 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (59 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
SW480
1
3
E-GEOD-2509, E-GEOD-18005, E-MEXP-1014, E-MTAB-37
HL-60
1
3
E-GEOD-24147, E-GEOD-5258, E-MTAB-37, E-GEOD-96
639 more value(s).


Cell type

studied in E-GEOD-21612, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (73 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
3
E-AFMX-5, E-TABM-145, E-GEOD-19069, E-GEOD-6740
mononuclear cell
2
E-GEOD-7307, E-MEXP-66
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
162 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-GEOD-3678, ... (107 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
4
E-GEOD-96, E-MTAB-62, E-GEOD-995, E-GEOD-1729
control
2
5
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20295, E-GEOD-3185, ... (7 experiments)
colon carcinoma
3
E-MTAB-57, E-GEOD-3726, E-MTAB-62
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
benign prostatic hyperplasia
3
E-MEXP-2034, E-GEOD-3868, E-MEXP-1243
glioblastoma
1
3
E-GEOD-4290, E-MTAB-62, E-MTAB-37, E-MEXP-567
301 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-4668, E-GEOD-5741, E-TABM-782, ... (42 experiments)

Factor Value U/D Experiments
none
6
12
E-GEOD-5741, E-TABM-868, E-GEOD-2803, E-GEOD-4668, E-MEXP-1958, ... (18 experiments)
ethanol
3
E-MEXP-2241, E-MEXP-1014, E-GEOD-3113
lipopolysaccharide
3
E-GEOD-3720, E-TABM-868, E-MEXP-1958
glutamine
2
E-MEXP-1335, E-MEXP-941
control
2
3
E-GEOD-4006, E-GEOD-3284, E-GEOD-3183, E-GEOD-5339, E-GEOD-995 ... (5 experiments)
baseline propofol
1
E-GEOD-4386
61 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
86
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, ... (13 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, E-GEOD-21589, ... (14 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19018, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-MEXP-1996, E-MEXP-1437, E-GEOD-1045, E-TABM-1029, E-GEOD-2466, ... (23 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-1648, E-GEOD-16363, ... (51 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-6927, ... (9 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, ... (10 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, ... (6 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.375 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM